Get the Stockscreener App
200.29
0.85%
1.69
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $200.29, with a volume of 2.09M.
It is up +0.85% in the last 24 hours and down -3.70% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$198.60
Open:
$199.54
24h Volume:
2.09M
Relative Volume:
1.51
Market Cap:
$29.05B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
19.31
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+6.18%
1M Performance:
-3.70%
6M Performance:
-18.17%
1Y Performance:
-21.83%
1-Day Range:
$198.21
$201.89
1-Week Range:
$187.25
$202.68
52-Week Range:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
200.29 | 29.05B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
404.70 | 143.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
155.92 | 42.96B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.80 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
38.87 | 32.87B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
AirSense 10 ClimateLineAir Heated Tube from ResMed Inc.quieter nights with smarter humidity - Ad-hoc-news.de
ResMed muted ahead of next earnings, shares trade steadily on NYSE - Ad-hoc-news.de
OLD National Bancorp IN Has $4.58 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. sees fresh institutional buying, shares hover near 200 dollars - Ad-hoc-news.de
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh - TradingView
Price to earnings forward of ResMed Inc. – NYSE:RMD - TradingView
Price to earnings forward of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – MUN:RMEA - TradingView
Price to sales forward of ResMed Inc. – NYSE:RMD - TradingView
ResMed clears key trading range, shares hold firm between support and resistance - Ad-hoc-news.de
Should you continue to hold Resmed stock in your portfolio? - MSN
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed clears a fresh 52-week high, shares extend their Nasdaq run - Ad-hoc-news.de
Why ResMed Inc (RMD) Is Set to Outperform the Market: Insights i - GuruFocus
Price to book forward of ResMed Inc. – NYSE:RMD - TradingView
ResMed Stock is Down 20% in 2026. Is It a Buying Opportunity or a Warning Sign? - TIKR.com
ResMed Inc. Actuals & Estimates (NYSE:RMD) - TradingView
ResMed (ASX:RMD) Stock Moves Higher — What Investors Should Know? - Kalkine
Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues? - Insider Monkey
Enterprise value to EBITDA forward of ResMed Inc. – NYSE:RMD - TradingView
ResMed opens the week with clear technical signals, shares trade in a defined range - Ad-hoc-news.de
Resmed Inc (RMD) Institutional Confidence - TradingKey
Did Morgan Stanley’s GLP-1 Downgrade Just Shift ResMed's (RMD) Investment Narrative? - Sahm
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Resmed Inc (RMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Should I buy CSL and ResMed shares right now? - The Motley Fool Australia
ResMed downgraded at Morgan Stanley on Philips re-entry and GLP-1 headwinds - MSN
ResMed edges higher after mixed analyst signals, shares trade near recent targets - AD HOC NEWS
Could ResMed (NYSE:RMD) Be Entering a New Chapter in Sleep Care? - Kalkine Media
ResMed trims KeyBanc price target, analyst views on the shares stay constructive - AD HOC NEWS
William Blair Maintains ResMed(RMD.US) With Buy Rating - Moomoo
KeyBanc Adjusts Price Target on ResMed to $266 From $290, Maintains Overweight Rating - marketscreener.com
ResMed Inc. (RMD) Stock Analysis: Unveiling A 39% Potential Upside Amidst Solid Growth - DirectorsTalk Interviews
Resmed Inc (RMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
KeyBanc Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $266 - Moomoo
Is ResMed (NYSE:RMD) Market Reset Creating New Interest? - Kalkine Media
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) was downgraded to a Hold Rating at Morgan Stanley - The Globe and Mail
Resmed Inc (RMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is ResMed stock underperforming the Dow? - MSN
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos - The Globe and Mail
Resmed Inc (RMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ResMed Loses Bull as Margin Outlook Moderates -- Market Talk - Moomoo
Resmed Closes Acquisition of Noctrix Health - Moomoo
ResMed Inc (RMD) Stock Down 3.9% -- Now Undervalued? GF Score: 9 - GuruFocus
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
Why ResMed (RMD) Shares Are Falling Today - Yahoo Finance
ResMed (RMD) Faces Downgrade Amid Market Concerns - GuruFocus
ResMed Shares Fall After Morgan Stanley Downgrade - Moomoo
Lobbying Update: $40,000 of RESMED CORP. lobbying was just disclosed - Quiver Quantitative
ResMed Inc. Stock 12‑Month Price Target Cut to $277.74, Implies 43% Upside - TradingView
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.91%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):